Tomoharu Matsui
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Increased MYC expression without MYC gene translocation in patients with the diffuse large B-cell-lymphoma subtype of iatrogenic immunodeficiency-associated lymphoproliferative disorders.
Journal: Journal of clinical and experimental hematopathology : JCEH
Published: September 13, 2021
Characteristics and predictors of post-transplant-associated hemophagocytic lymphohistiocytosis in adults.
Journal: International journal of hematology
Published: September 22, 2020
Corrigendum to 'Comparative Study of Tacrolimus and Short-Term Methotrexate: 2-Day versus 3-Day Methotrexate as Graft-versus-Host-Disease Prophylaxis after Umbilical Cord Blood Transplantation in Adults' [Biology of Blood and Marrow Transplantation 26/2 (2020) 367-372].
Journal: Transplantation and cellular therapy
Published: March 16, 2020
A Case of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Achieving Complete Molecular Response with Ponatinib Therapy despite the Development of Hemorrhagic Stroke during Remission Induction Chemotherapy
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: November 22, 2019
A Case of Synchronous Diffuse Large B-Cell Lymphoma of the Right Breast and Invasive Ductal Carcinoma of the Left Breast
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: November 22, 2019
Elevated C-reactive protein level is associated with poor prognosis in follicular lymphoma patients undergoing rituximab-containing chemotherapy.
Journal: International journal of hematology
Published: October 20, 2019
Comparative Study of Tacrolimus and Short-Term Methotrexate: 2-Day versus 3-Day Methotrexate as Graft-versus-Host-Disease Prophylaxis after Umbilical Cord Blood Transplantation in Adults.
Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
Published: July 14, 2019
Refined Disease Risk Index for Hematological Malignancies, Including Rare Disorders, After Allogeneic Stem Cell Transplantation.
Journal: Transplantation proceedings
Published: July 05, 2019
Showing 1-8 of 8
Last Updated: 09/26/2026